Astellas Pharma Inc. announced changes in its Global Commercial Leadership Team reporting to Chief Commercial Officer Yukio Matsui aligned with the focuses for the new Corporate Strategic Plan 2021 (CSP2021).

“Our Commercial strategy allows us to focus our efforts in support of our current and future products while ensuring our team members are prepared with the capabilities, training, and tools to efficiently deliver value to our patients,” said Matsui. “I have great confidence in these leaders and trust their efforts will allow us to deliver our commitments to the CSP2021.”

Phil Tennant promoted to Senior Vice President and Head of the Global Oncology Strategic Brand Marketing (SBM).

In his new role, Tennant will oversee the global teams supporting priority oncology brands, including marketed and pre-launch products.

Tennant joined Astellas in 2019 after working nearly 30 years in the pharmaceutical industry. Most recently, Tennant served as Vice President and Brand General Manager for the Global Oncology New Products SBM at Astellas.

Txema Sanz promoted to Senior Vice President and Head of the Global Medical Specialties SBM.

Sanz will continue to provide leadership for the global teams supporting priority non-oncology products, excluding Gene/Cell Therapies.  

With more than 20 years of industry experience, Sanz previously held the position of General Manager of Astellas in the UK. He most recently served as Vice President and Brand General Manager for the Global Specialty Products SBM, which was renamed as Medical Specialties SBM.

Jun Kono assigned as Senior Vice President and Head of the Global Commercial Strategy team.

Kono is responsible for global commercial functions including Commercial Strategy and Planning, New Product Planning, Established Product Marketing, CSP Workstream Lead and a new Commercial Communications team.

Based in Chicago, Kono most recently served as Senior Vice President of the Global Commercial Strategy and Capabilities team, bringing more than 25 years of experience working for Astellas.

Damien Bailly promoted to Senior Vice President and Head of the Global Commercial Capabilities team.

In his new global role, Bailly will be responsible for global oversight of four core commercial capability areas, including Commercial Capabilities, Learning and Development; Commercial Insights; Congresses and Events; and Omni-Channel Operations.

For the last two years, Bailly has served as Vice President, Commercial Capability and Strategy Lead for the Established Markets Commercial Division. Based in France, Bailly has worked in the pharmaceutical industry for nearly 30 years.

Renee-Helene Charollais assigned as Senior Vice President and Head of the Global Market Access and Pricing team.

In this role, Charollais will lead a global team that partners with local affiliates to provide patients with access to Astellas treatments and determine product pricing.

Since joining Astellas in 2016, Charollais has served in regional leadership roles in Europe and was most recently the Senior Vice President and Brand General Manager for the XTANDI® (enzalutamide) SBM. With nearly 30 years of experience, she has been assigned to oversee the Global Market Access and Pricing team.

Astellas also made a change in the US commercial organization, in which Lynn Fenicchia will continue to report directly to US President, Mark Reisenauer.

Lynn Fenicchia was promoted to Senior Vice President overseeing the new Market Access and Commercial Capabilities team within the US Commercial organization.

In this role, Fenicchia is responsible for setting the strategic agenda for Astellas’ largest market, overseeing the critical link to healthcare providers, payers and patients to ensure access to medicines, and operationalizing best in class commercial capabilities to support these efforts.

Fenicchia joined Yamanouchi Pharmaceutical Co., Ltd. in 2003, which merged with Fujisawa Pharmaceutical Co., Ltd. to create Astellas. Since joining Astellas, she has held multiple roles, including Vice President of Commercial Strategy and Operations and Vice President of Sales, Medical Specialties.